Drugs / F573
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04820049 | Feb 2021 → Aug 2022 | — | Beijing Continent Pharmaceutical Co, Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05689645 | Mar 2023 → Sep 2026 overdue | acute liver failure, chronic liver failure | Beijing Continent Pharmaceutical Co, Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | F573 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05689645 ↗ |
| Route | Intramuscular | “intramuscular injection (IM)” NCT05689645 ↗ |